-+ 0.00%
-+ 0.00%
-+ 0.00%

Silexion Therapeutics Announces Preclinical Data Demonstrating SIL204 Efficacy In Human Lung Cancer Cell Lines

Benzinga·07/09/2025 12:32:47
Listen to the news

The study revealed significant dose-dependent inhibition in lung cancer cells harboring KRAS G12D mutations, with notable efficacy, highlighting SIL204's potential as a versatile therapeutic for lung cancer. The results also support Silexion's lipid-conjugated delivery system for enhancing SIL204 drug entrance into tumor cells; overcoming a known barrier for siRNA technology and one which is critical for therapeutic efficacy in solid tumors.